Intensity Therapeutics

$INTS Founder & CEO Lewis Bender shares his perspective on early observations from the Phase 2 INVINCIBLE-4 study evaluating INT230-6 in #TNBC. Preliminary data showed 71.4% pCR and 44% fewer grade ≥3 adverse events vs SOC alone. Read more: bit.ly/4lpFI13

Lewis Bender, Founder and CEO of $INTS, shares a guest column with Drug Delivery Leader on the potential of intratumoral therapy. The article also highlights #INT2306, Intensity’s investigational therapy in #clinicaltrials. Read more: bit.ly/3Nu2mJf #CancerResearch

$INTS provides an update on the Phase 2 INVINCIBLE-4 study in #TNBC. Preliminary observations showed 71.4% pCR with INT230-6 prior to SOC vs 33% with SOC alone, and 44% fewer grade ≥3 adverse events. Read more: bit.ly/4lpFI13 #ClinicalTrials

In recognition of Women’s History Month, $INTS highlights the role innovation plays in advancing care for women affected by cancer. $INTS continues to advance #INT2306 to improve outcomes for patients with difficult-to-treat #breastcancer. #WomensHistoryMonth #WomenInHealth

$INTS announces that it has received formal notice from the Listings Qualifications staff of The @Nasdaq Stock Market that the company has regained compliance with #Nasdaq Listing Rule 5550(a)(2). Full press release here: bit.ly/4beoz69

In a new @ClinicalLeader1 article, $INTS' CEO, Lewis Bender, shares best practices for adaptive, open-label Phase 3 RCTs and how these designs can accelerate timelines while maintaining regulatory rigor. Read more: bit.ly/403fXdk #Oncology #ClinicalTrials

#ICYMI: @jacobsen35775 of @afurtherinquiry spoke with Lew Bender on how INT230-6 is advancing new approaches in #cancertreatment. Catch up here: bit.ly/4hFlqim $INTS #ClinicalTrials

Great to see Kimberly A. Guedes, VP of Operations at $INTS, take part in industry discussions at the @marcusevans Evolution Summit last month. The panel focused on how lean #biotech teams can maximize impact through strategic collaboration. #ClinicalDevelopment #IndustryEvents

$INTS is advancing a novel intratumoral approach that kills cancer cells in a manner that activates the immune system, with the goal of improving patient outcomes and minimizing severe side effects. Learn more: bit.ly/47qAopx #IntensityTherapeutics #CancerResearch

This #NationalCancerPreventionMonth underscores the importance of prevention, awareness, and continued progress in #cancercare. $INTS is developing innovative intratumoral therapies designed to activate the immune system and improve outcomes for patients with solid tumors. In a presurgical setting, such a product may delay the onset of the disease recurrence.

Cancer goes beyond what’s visible. On a recent Progress, Potential, and Possibilities podcast, Lewis Bender discusses how $INTS' intratumoral approach targets both tumors and unseen #cancer cells. Full episode on @YouTube: bit.ly/4pP9pJP #BiotechPodcast

#IntensityTherapeutics is proud to highlight Doranne Frano, our Regulatory Affairs and Quality Control leader, with 40+ years of experience working in pharma, biotech, & regulatory compliance. Learn more about $INTS' leadership team: bit.ly/4krq97F #EmployeeSpotlight

#Breastcancer continues to impact hundreds of thousands, with @AmericanCancer estimating over 321,000 new invasive cases in the U.S. in 2026. $INTS is advancing #INT2306 to activate the immune system and improve patient outcomes. Learn more: bit.ly/40ipTjJ

This #WorldCancerDay, we stand with patients, families, and caregivers impacted by cancer worldwide. $INTS is advancing a novel intratumoral approach designed to target tumors and activate the immune response to help improve outcomes across #solidtumors. #CancerAwareness

On a recent @pharmaphorum Podcast, Lew Bender, CEO of #IntensityTherapeutics, shared clinical observations from the INT230-6 Phase 1/2 trial, including encouraging outcomes in #sarcoma that supported the move into Phase 3. Catch up on the full episode: bit.ly/4rS4n1t $INTS  #ClinicalTrials

#ICYMI: Lew Bender, CEO of $INTS, shared insights on #Intensity’s intratumoral approach and the differentiation of INT230-6 in a feature with Drug Development & Delivery. Full feature: bit.ly/4q0K0Ot #INT2306 #CancerResearch

$INTS' CEO, Lew Bender, joined @irat1onal on the Progress, Potential, and Possibilities podcast to discuss  #Intensity’s intratumoral approach and the science behind #INT2306. Watch or listen to the full episode on @YouTube: bit.ly/4pP9pJP

#IntensityTherapeutics delivered meaningful clinical and corporate progress in 2025, including continued advancement of the INVINCIBLE-4 Phase 2 study and peer-reviewed validation of #INT2306. Read more: bit.ly/4qIBe7a $INTS #ClinicalResearch

Last week, the $INTS leadership team attended the @jpmorg Healthcare Conference in San Francisco, where they connected with healthcare investment bankers, analysts, potential strategic pharma partners, and industry peers. #JPM2026 #JPM26